Introduction: Breast cancer is the commonest cancer and second cause of cancer related death in United States. As reported by various studies worldwide and India, there is significant increase in incidence and cancer related mortality reported in India. In India Breast cancer ranked one with age adjusted rate as high as 25.8 per lakh woman.

Material and Methods: This was retrospective study data archives from Department of Pathology and Department of Radiation Oncology, State Cancer Institute, Indira Gandhi Institute, Patna, Bihar. Patients diagnosed with breast carcinoma and available reports of serum hormonal status and HER2 + Ki 67 status by immunohistochemistry were analyzed.

Results: Total 210 cases were analyzed who attend our department for treatment in 6 months period. Commonest age group we found in our study was 41 to 50 years, 51 to 60 years cases of 22.6%, 12.3% cases 61 to 70 years. 27.5% cases were above 55 year and 72.5% were <55 years of age.

Conclusion: Breast cancer is more common in younger age group as compared to older age group. Advanced stage patient was highest in our study. Ki-67 range was 30-40%, commonest in our study

Keywords: Breast Carcinoma; Breast Cancer

References

1. Jemal A., et al. “Global cancer statistics”. CA: A Cancer Journal for Clinicians 61 (2011): 69-90.
2. Ferlay J., et al. “Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012”. International Journal of Cancer5 (2015): E359-386.
3. Malvia S., et al. “Epidemiology of breast cancer in Indian women”. Asia-Pacific Journal of Clinical Oncology 4 (2017): 289-295.
4. Gupta A., et al. “A review of breast cancer awareness among women in India: Cancer literate or awareness deficit?” European Journal of Cancer Oxf Engl.14 (1990): 2058-2066.
5. Albain KS., et al. “Breast cancer outcome and predictor of outcome: are there age differentials?” Journal of the National Cancer Institute Monographs 16 (1994): 35-42.
6. Kollias J., et al. “Early-onset breast cancer-histopathological and prognostic considerations”. British Journal of Cancer 75 (1997): 1318-1323.
7. Shannon C and Smith IE. “Breast cancer in adolescents and young women”. European Journal of Cancer 39 (2003): 2632-2642.
8. Anders CK., et al. “Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression”. Journal of Clinical Oncology 26 (2008): 3324-3330.
9. El Saghir NS., et al. “Effects of young age at presentation on survival in breast cancer”. BMC Cancer 6 (2006): 194.
10. Crossref ISI Google Scholar.
11. Gajdos C., et al. “Stage 0 to stage III breast cancer in young women”. Journal of the American College of Surgeons 190 (2000): 523-529.
12. Hammond MEH., et al. “American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version)”. Archives of Pathology and Laboratory Medicine 7 (2010): 48-72.
13. Leong ASY and Zhuang Z. “The Changing Role of Pathology in Breast Cancer Diagnosis and Treatment”. Pathobiology2 (2011): 99-114.
14. Bland KI., et al. “The national cancer data base 10-year survey of breast carcinoma treatment at hospitals in the United States”. Cancer 83 (1998): 1262-1273.
15. Elkhuizen PH., et al. “Local recurrence after breast-conserving therapy for invasive breast cancer: high incidence in young patients and association with poor survival”. International Journal of Radiation Oncology, Biology, Physics 40 (1998): 859-867.
16. Ghosh J., et al. “Estrogen, progesterone and HER2 receptor expression in breast tumors of patients, and their usage of HER2-targeted therapy, in a tertiary care centre in India”. Indian Journal of Cancer 48 (2011): 391-396.
17. Manjunath S., et al. “Estrogen receptor negative breast cancer in India: Do we really have higher burden of this subtype?” Indian Journal of Surgical Oncology 2 (2011): 122-125.
18. Rajan G., et al. “Estrogen and progesterone receptor status in breast cancer: A cross-sectional study of 450 women in Kerala, South India”. World Journal of Surgical Oncology 12 (2014): 120.
19. Singh R., et al. “Receptor expression in patients in semi urban India”. Journal of Cancer Research Therapy 10 (2014): 26-28.
20. Mukherjee G., et al. “Analysis of clinico-pathological characteristics of Indian breast cancers shows conservation of specific features in the hormone receptor sub-types”. Journal of Integrative Oncology 5 (2016): 159.
21. Bustreo S., et al. “Optimal ki67 cut-off for luminal breast cancer prognostic evaluation: A large case series study with a long-term follow-up”. Breast Cancer Research and Treatment 157 (2016): 363-371.
22. Anderson WF., et al. “Comparison of age distribution patterns for different histopathologic types of breast carcinoma”. Cancer Epidemiology, Biomarkers and Prevention 15 (2006): 1899-1905.
23. Anderson WF., et al. “Shifting breast cancer trends in the United States”. Journal of Clinical Oncology 25 (2007): 3923-3929.
24. Goldhirsch A., et al. “Personalizing the treatment of women with early breast cancer: Highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013”. Annals of Oncology 24 (2013): 2206-2223.
25. Perou CM., et al. “Molecular portraits of human breast tumours”. Nature 406 (2000): 747-752.
26. Rodríguez-Cuevas S., et al. “Breast carcinoma presents a decade earlier in Mexican women than in women in the United States or European countries”. Cancer 91 (2001): 863-868.
27. Nissan A., et al. “Clinical profile of breast cancer in Arab and Jewish women in the Jerusalem area”. American Journal of Surgery 188 (2004): 62-7.
28. El Saghir NS., et al. “Age distribution of breast cancer in Lebanon: increased percentages and age adjusted incidence rates of younger-aged groups at presentation”. Lebanese Medical Journal 50 (2002): 3-9.
29. Swanson GM and Lin CS. “Survival patterns among younger women with breast cancer: the effects of age, race, stage, and treatment”. Journal of the National Cancer Institute Monographs 16 (1994): 69-77.
30. Rapiti E., et al. “Survival of young and older breast cancer patients in Geneva from 1990 to 2001”. European Journal of Cancer 41 (2005): 1446-1452.
31. Agarwal G., et al. “Spectrum of Breast Cancer in Asian Women”. World Journal of Surgery5 (2007): 1031-1040.
32. “Breast cancer in developing countries”. Lancet9701 (2009): 1567.
33. Desai SB., et al. “Hormone receptor status of breast cancer in India: a study of 798 tumours”. Breast 5 (2000): 267-270.
34. Redkar AA., et al. “Estrogen and progesterone receptors measurement in breast cancer with enzyme-immunoassay and correlation with other prognostic factors”. Indian Journal of Medical Research 96 (1992): 1-8.
35. Mudduwa LKB. “Quick score of hormone receptor status of breast carcinoma: Correlation with the other clinicopathological prognostic parameters”. Indian Journal of Pathology and Microbiology 2 (2009): 159-163.
36. Chariyalertsak S., et al. “Immunohistochemical detection of estrogen and progesterone receptors in primary breast cancer”. Asian Pacific Journal of Allergy and Immunology 4 (1998): 161-167.
37. Li CI., et al. “Incidence of Invasive Breast Cancer by Hormone Receptor Status From 1992 to 1998”. Journal of Clinical Oncology1 (2003): 28-34.
38. DM Barnes and A M Hanby. “Oestrogen and progesterone receptors in breast cancer: past, present, and future”. Histopathology (2001): 3832714.
39. Gupta A., et al. “Triple negative breast cancer - An overview and review of literature”. Asian Journal of Medical Sciences 3 (2012): 16-20.
40. B Siddiqui., et al. “Trends in Molecular Classification of Breast Carcinoma in a tertiary Health care centre: A 5 year retrospective study”. International Archives of BioMedical and Clinical Research (2016): 226972.
41. S Dawood., et al. “Prognosis of Women with Metastatic Breast Cancer by HER2 Status and Trastuzumab Treatment: An Institutional- Based Review”. Journal of Clinical Oncology (2010): 281928.
42. R V Kumar., et al. “Estrogen receptor, Progesterone receptor, and human epidermal growth factor receptor-2 status in breast cancer: A retrospective study of 5436 women from a regional cancer center in South India”. South Asian Journal of Cancer1 (2018): 7-10.
43. N Daniel., et al. “Study of hormone receptor status and HER/2-neu expression in breast malignancies and its implication in molecular subtyping in a tertiary care hospital”. 10.18231%2Fj.ijpo.2020.108.
44. RCM Fernandes., et al. “Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinoma”. Histopathology (2009): 55334652.
45. R Kaul., et al. “Hormone Receptor Status of Breast Cancer in the Himalayan Region of Northern India”. Indian Journal of Surgery (2011): 731912.
46. N Kumar., et al. “Prevalence of molecular subtypes of invasive breast cancer: A retrospective study”. Medical Journal Armed Forces India (2015): 7132548.

Citation

Citation: Seema Devi., et al. “Profile of Carcinoma Breast Patients”.Acta Scientific Cancer Biology 8.4 (2024): 03-09.

Copyright

Copyright: © 2024 Seema Devi., et al. “Study of p16INK4a Immunostaining as Specific Biomarker in the diagnosis of Cervical Intraepithelial Neoplasia and This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.